It takes a village: New approaches to I/O with innovative partnership models

12:00 PM - 12:45 PM (EDT), Wednesday, June 16, 2021
Search General Info
Search Education
Search Partnering Companies

Collaboration among industry stakeholders is essential to discovering and developing emerging I/O approaches – where many see a promise in revolutionizing treatments for all types of cancer.  In 2020, despite the challenges of the COVID-19 pandemic, immuno-oncology assets represented 49% of oncology licensing transactions (out of a total value of $56B, Nature) and 66% of total disclosed deal value (out of a total value of $133B, Nature). With new partnerships and deals being announced on a near-daily basis, 2021 appears to be staying on trend. This insider panel will explore collaboration success stories and lessons learned as well different models for structuring partnerships to drive the development of novel I/O therapies and progress for cancer patients.

Sponsored By
Associate Partner
McKinsey & Co
Head of the Oncology Therapeutic Area Unit
President and Chief Executive Officer
Turnstone Biologics
Chief Executive Officer
Maverick Therapeutics